Home » Stocks » NGM

NGM Biopharmaceuticals, Inc. (NGM)

Stock Price: $26.77 USD 0.02 (0.07%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 2.06B
Revenue (ttm) 87.37M
Net Income (ttm) -102.49M
Shares Out 68.48M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $26.77
Previous Close $26.75
Change ($) 0.02
Change (%) 0.07%
Day's Open 26.79
Day's Range 26.07 - 27.90
Day's Volume 72,046
52-Week Range 14.93 - 32.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.29% and 1.17%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 day ago - Zacks Investment Research

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutic...

1 week ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more...

1 month ago - Zacks Investment Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 14.89% and -14.45%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutic...

2 months ago - GlobeNewsWire

--Humanized IgG1 monoclonal antibody engineered to potently inhibit complement C3, with the potential for extended every eight-week dosing-- --CATALINA Phase 2 study of NGM621 in patients with geographi...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

4 months ago - GlobeNewsWire

– Event to showcase NGM's multi-therapeutic area p ipeline , including its oncology por tfolio and Geographic Atrophy and NASH programs – 

5 months ago - GlobeNewsWire

--Single and multiple intravitreal injections of NGM621 appeared safe and well tolerated in first-in-human study, with no patients experiencing serious adverse events, drug-related AEs, intraocular infl...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

5 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...

8 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -15.15% and -3.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

--Sustained progress across clinical development programs spanning liver,  retinal and metabolic diseases and cancer-- --Aldafermin continues to advance toward late-stage clinical development in non-a...

8 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., July 31, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeuti...

9 months ago - GlobeNewsWire

-- Multicenter, randomized, double-masked, sham-controlled study will evaluate safety and efficacy of intravitreal injections of NGM621 every four or eight weeks for 48 weeks -- -- GA is a progressive,...

9 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM) (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, ...

11 months ago - GlobeNewsWire

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

-- Initiated Phase 2b ALPINE 4 clinical study of aldafermin (formerly NGM282) in  non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4 fibrosis) -- -- Continuing enrollment in...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM) today announced that, due to public health and safety concerns related to the coronavirus (COVI...

11 months ago - GlobeNewsWire

Market watchers are looking to the insiders, hoping insights from their activity can steer them towards returns.

Other stocks mentioned: AXDX, CDLX, GIII, OPK
1 year ago - InvestorPlace

NGM Biopharmaceuticals Inc (NASDAQ: NGM), which went public about a year back, has seen its shares trade mostly below the IPO price of $16.

1 year ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, toda...

1 year ago - GlobeNewsWire

Strong results on multiple measures put the company's drug candidate firmly in the NASH discussion.

1 year ago - The Motley Fool

Shares popped after the clinical-stage biotech reported upbeat clinical results.

1 year ago - The Motley Fool

NGM Biopharmaceuticals Inc (NASDAQ: NGM) is advancing strongly on above-average volume Monday following a positive clinical data readout.

1 year ago - Benzinga

--Study to evaluate potential of GDF15/GFRAL pathway inhibition to  block tumor-associated weight loss and tumor growth-- --CACS, an uncontrolled wasting syndrome, is a common co-morbidity of cancer and...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for ...

1 year ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor NGM Biopharmaceuticals.

1 year ago - Zacks Investment Research

Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.

Other stocks mentioned: ACIU, ASND, EYEN, SAGE
1 year ago - Zacks Investment Research

NGM Biopharmaceuticals announces positive data from Phase 2b study treating patients with NASH using NGM282.

1 year ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for ...

1 year ago - GlobeNewsWire

Tough industry conditions and company-specific issues hit these stocks.

Other stocks mentioned: ACB, SRNE
1 year ago - The Motley Fool

About NGM

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for u... [Read more...]

Industry
Biotechnology
IPO Date
Apr 4, 2019
CEO
David Woodhouse
Employees
210
Stock Exchange
NASDAQ
Ticker Symbol
NGM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for NGM stock is "Strong Buy." The 12-month stock price forecast is 39.63, which is an increase of 48.04% from the latest price.

Price Target
$39.63
(48.04% upside)
Analyst Consensus: Strong Buy